Clinical trial
Combination Chemotherapy With or Without Trastuzumab in Treating Women With…
NCT00021255 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00021255 |
|---|---|
| Title | Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer |
| Official title | Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed By Docetaxel (AC-T) With Doxorubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab (Herceptin)(AC-TH) and With Docetaxel, Carboplatin and Trastuzumab (TCH) In The Adjuvant Treatment Of Node… |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Cancer International Research Group (CIRG) |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Neoplasms |
| Intervention type | Drug |
| Interventions | Doxorubicin, Cyclophosphamide, Docetaxel, Herceptin, Carboplatin |
| Enrollment | 3,222 |
| Start date | Apr 1, 2001 |
| Primary completion | Dec 1, 2014 |
| Completion | Dec 1, 2014 |
| First posted | Jan 27, 2003 |
| Last update posted | Nov 15, 2016 |
| Countries | Argentina, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Colombia, Croatia, Czechia, Egypt and 30 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: